p.161 抽出テキスト

オイドの変更,投与経路の変更を条件付きで推奨すると結論した。

【引用文献】1) Tsukuura H, Miyazaki M, Morita T, et al. Efficacy of Prophylactic Treatment for Oxycodone‒ Induced Nausea and Vomiting Among Patients with Cancer Pain(POINT): a randomized, placebo‒controlled, double‒blind trial. Oncologist 2018; 23: 367‒74 2) Inoue S, Saito Y, Tsuneto S, et al. A randomized, double‒blind, non‒inferiority study of hydromorphone hydrochloride immediate‒release tablets versus oxycodone hydrochloride immediate‒release powder for cancer pain: efficacy and safety in Japanese cancer patients. Jpn J Clin Oncol 2018; 48: 542‒7 3) Inoue S, Saito Y, Tsuneto S, et al. A double‒blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Jpn J Clin Oncol 2018; 48: 442‒9 4) Inoue S, Saito Y, Tsuneto S, et al. A randomized, double‒blind study of hydromorphone hydrochloride extended‒release tablets versus oxycodone hydrochloride extended‒release tablets for cancer pain: efficacy and safety in Japanese cancer patients(EXHEAL: a Phase III study of EXtended‒release HydromorphonE for cAncer pain reLief). J Pain Res 2017; 10: 1953‒62 5) Nosek K, Leppert W, Nosek H, et al. A comparison of oral controlled‒release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther 2017; 11: 2409‒19 6) Shimoyama N, Gomyo I, Teramoto O, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 2015; 45: 189‒96 7) Hardy J, Daly S, McQuade B, et al. A double‒blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid‒induced nausea and emesis in cancer patients. Support Care Cancer 2002; 10: 231‒6 8) Hunt R, Fazekas B, Thorne D, et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage 1999; 18: 111‒9 9) Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled‒release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998; 38: 74‒81 10) Bruera E, Fainsinger R, Spachynski K, et al. Clinical efficacy and safety of a novel controlled‒ release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13: 1520‒7 11) De Conno F, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid‒naive cancer patients with pain. J Clin Oncol 1995; 13: 1004‒8 12) Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639‒46 13) Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998; 2: 53‒62 14) Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long‒term control of chronic pain in cancer patients. Front Biosci 2007; 12: 1291‒9 15) Marinangeli F, Ciccozzi A, Aloisio L, et al. Improved cancer pain treatment using combined fentanyl‒TTS and tramadol. Pain Pract 2007; 7: 307‒12 16) Rodriguez RF, Bravo LE, Castro F, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double‒blind comparative trial. J Palliat Med 2007; 10: 56‒60 17) Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo‒controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008; 36: 117‒25 18) Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to metha-

done in cancer patients? a randomised clinical phase II trial. Eur J Cancer 2011; 47: 2463‒70